Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283790 · ClinicalTrials.gov registry record · Phase 4
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00283790 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 36 participants.
The verdict
NCT00283790, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
Interventions
- DRUG zolpidem tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283790
The ClinicalTrials.gov registry entry for NCT00283790 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zolpidem tartrate is the first listed.
NCT00283790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283790 about?
NCT00283790 is a clinical study titled "Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo". Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
What is the current status of trial NCT00283790?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2006-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00283790?
The interventions under investigation include: zolpidem tartrate (DRUG).
Who is sponsoring clinical trial NCT00283790?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.